AbbVie on Twitter
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
June 07, 2017- First Phase 3 clinical trial shows positive results for upadacitinib and a safety profile consistent with that observed in Phase 2 clinical trials (1)(2)(3)
-
May 09, 2017- Phase 2 study showed positive results in a moderately to severely active Crohn's disease patient population, the majority of whom had previously failed two or more biologics
-
May 04, 2017- Phase 2 late-breaking study evaluates upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderately to severely active Crohn's disease, the majority of whom had failed two or more biologics
-
March 30, 2017- HUMIRA is now the first-and-only biologic treatment with fingernail psoriasis data in its U.S. prescribing information for moderate to severe chronic plaque psoriasis patients
-
January 09, 2017- Collaborations will focus on key therapeutic areas, including oncology and immunology
-
November 14, 2016- If approved by the European Commission, HUMIRA will be the first and only treatment option for patients aged 12 and older with hidradenitis suppurativa (HS), a painful, chronic inflammatory skin disease.
-
September 26, 2016- New Phase 2 open-label extension data to be presented on investigational biologic compound risankizumab, an anti-IL-23 monoclonal antibody, currently under investigation for moderate to severe chronic plaque psoriasis
-
July 19, 2016- Chastain, whose son was recently diagnosed with Crohn's disease, shares her story through My IBD Game Plan and encourages people living with inflammatory bowel diseases to work with their healthcare providers to create individualized plans to live well with these diseases
-
July 07, 2016- Data from Phase 3 randomized, placebo controlled trial demonstrates that 46.6 percent of adult patients with moderate to severe psoriasis treated with HUMIRA® achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis
Our history
 |
Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more
Societal impact
 |
Our commitment to science is a commitment to better our society. Read our 2023 ESG report
Ratings and recognition
 |
We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more
Annual report
 |
See our latest 2023 Annual Report on Form 10-K. Learn more
